Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Supportive Care in Cancer
Erschienen in: Supportive Care in Cancer 5/2020

14.12.2019 | Special Article

Systematic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines

Erschienen in: Supportive Care in Cancer | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To update the 2013 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) clinical practice guidelines on oral cryotherapy for the management of oral mucositis (OM) caused by cancer therapies.

Methods

A systematic review was conducted by the Mucositis Study Group of MASCC/ISOO. The evidence for each intervention for specific cancer treatment modalities was assigned a level of evidence (LoE). The findings were added to the database used to develop the 2013 MASCC/ISOO clinical practice guidelines. Based on the LoE, the guidelines were set as: recommendation, suggestion, or no guideline possible.

Results

A total of 114 papers were identified: 44 from PubMed and 70 from Web of Science. After abstract triage and merging with the 2013 database, 36 papers were reviewed. The LoE for prevention of OM with oral cryotherapy in patients undergoing autologous hematopoietic stem cell transplant using high-dose melphalan conditioning protocols was upgraded, and the guideline changed to recommendation. Additionally, the recommendation for prevention of OM with oral cryotherapy in patients receiving bolus 5-fluorouracil for the treatment of solid tumors was confirmed. No guidelines were possible for other clinical settings.

Conclusions

The evidence supports recommendations for the use of oral cryotherapy for the prevention of OM for either (i) patients undergoing autologous hematopoietic stem cell transplant with high-dose melphalan conditioning protocols or (ii) patients receiving bolus 5-fluorouracil chemotherapy.
Literatur
1.
Jones JA, Avritscher EB, Cooksley CD, Michelet M, Bekele BN, Elting LS (2006) Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer 14:505–515PubMedCrossRef
2.
McGuire DB, Fulton JS, Park J, Brown CG, Correa ME, Eilers J, Elad S, Gibson F, Oberle-Edwards LK, Bowen J, Lalla RV, Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral O (2013) Systematic review of basic oral care for the management of oral mucositis in cancer patients. Support Care Cancer 21:3165–3177CrossRef
3.
Lalla RV, Saunders DP, Peterson DE (2014) Chemotherapy or radiation-induced oral mucositis. Dent Clin N Am 58:341–349PubMedCrossRef
4.
Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, McGuire DB, Migliorati C, Nicolatou-Galitis O, Peterson DE, Raber-Durlacher JE, Sonis ST, Elad S, Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in C, International Society of Oral O (2014) MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 120:1453–1461CrossRef
5.
Villa A, Sonis S (2016) Toxicities associated with head and neck cancer treatment and oncology-related clinical trials. Curr Probl Cancer 40:244–257PubMedCrossRef
6.
Walladbegi J, Gellerstedt M, Svanberg A, Jontell M (2017) Innovative intraoral cooling device better tolerated and equally effective as ice cooling. Cancer Chemother Pharmacol 80:965–972PubMedPubMedCentralCrossRef
7.
Karagozoglu S, Filiz Ulusoy M (2005) Chemotherapy: the effect of oral cryotherapy on the development of mucositis. J Clin Nurs 14:754–765PubMedCrossRef
8.
Mahood DJ, Dose AM, Loprinzi CL, Veeder MH, Athmann LM, Therneau TM, Sorensen JM, Gainey DK, Mailliard JA, Gusa NL et al (1991) Inhibition of fluorouracil-induced stomatitis by oral cryotherapy. J Clin Oncol 9:449–452PubMedCrossRef
9.
Walladbegi J, Smith SA, Grayson AK, Murdoch C, Jontell M, Colley HE (2018) Cooling of the oral mucosa to prevent adverse effects of chemotherapeutic agents: an in vitro study. J Oral Pathol Med 47:477–483PubMedCrossRef
10.
Lilleby K, Garcia P, Gooley T, McDonnnell P, Taber R, Holmberg L, Maloney DG, Press OW, Bensinger W (2006) A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 37:1031–1035PubMedCrossRef
11.
Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, Elting LS, Fox PC, Cooksley C, Sonis ST, Mucositis Study Section of the Multinational Association for Supportive Care in C, International Society for Oral O (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100:2026–2046CrossRef
12.
Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, Migliorati CA, McGuire DB, Hutchins RD, Peterson DE, Mucositis Study Section of the Multinational Association of Supportive Care in C, the International Society for Oral O (2007) Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109:820–831CrossRef
13.
Peterson DE, Ohrn K, Bowen J, Fliedner M, Lees J, Loprinzi C, Mori T, Osaguona A, Weikel DS, Elad S, Lalla RV, Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral O (2013) Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy. Support Care Cancer 21:327–332CrossRef
14.
Ranna VC, K ; Castillo, D; Porcello, L; Vaddi, A; Lalla, R.; Bossi, P; Elad, S (2019) Development of the MASCC/ISOO clinical practice guidelines for Mucositis: an overview of the methods. Jounal Supportive Care in Cancer (In Press)
15.
Somerfield MR, Pfister DG, Bennett CL, Recht A, Smith TJ, Weeks JC, Winn RJ, Durant JR (2000) ASCO clinical practice guidelines: process. Progress, Pitfalls, and Prospects Classic Papers and Current Comments 4:881–886
16.
Hadorn DC, Baker D, Hodges JS, Hicks N (1996) Rating the quality of evidence for clinical practice guidelines. J Clin Epidemiol 49:749–754PubMedCrossRef
17.
18.
Askarifar M, Lakdizaji S, Ramzi M, Rahmani A, Jabbarzadeh F (2016) The effects of oral cryotherapy on chemotherapy-induced oral mucositis in patients undergoing autologous transplantation of blood stem cells: a clinical trial. Iran Red Crescent Med J 18:e24775PubMedPubMedCentralCrossRef
19.
Salvador P, Azusano C, Wang L, Howell D (2012) A pilot randomized controlled trial of an oral care intervention to reduce mucositis severity in stem cell transplant patients. J Pain Symptom Manag 44:64–73CrossRef
20.
Svanberg A, Birgegard G, Ohrn K (2007) Oral cryotherapy reduces mucositis and opioid use after myeloablative therapy--a randomized controlled trial. Support Care Cancer 15:1155–1161PubMedCrossRef
21.
Svanberg A, Ohrn K, Birgegard G (2010) Oral cryotherapy reduces mucositis and improves nutrition-a randomised controlled trial. J Clin Nurs 19:2146–2151PubMedCrossRef
22.
Gori E, Arpinati M, Bonifazi F, Errico A, Mega A, Alberani F, Sabbi V, Costazza G, Leanza S, Borrelli C, Berni M, Feraut C, Polato E, Altieri MC, Pirola E, Loddo MC, Banfi M, Barzetti L, Calza S, Brignoli C, Bandini G, De Vivo A, Bosi A, Baccarani M (2007) Cryotherapy in the prevention of oral mucositis in patients receiving low-dose methotrexate following myeloablative allogeneic stem cell transplantation: a prospective randomized study of the Gruppo Italiano Trapianto di Midollo Osseo nurses group. Bone Marrow Transplant 39:347–352PubMedCrossRef
23.
Aisa Y, Mori T, Kudo M, Yashima T, Kondo S, Yokoyama A, Ikeda Y, Okamoto S (2005) Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients. Support Care Cancer 13:266–269PubMedCrossRef
24.
Batlle M, Morgades M, Vives S, Ferra C, Oriol A, Sancho JM, Xicoy B, Moreno M, Magallon L, Ribera JM (2014) Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high-dose melphalan for autologous stem cell transplantation for lymphoma and myeloma. Eur J Haematol 93:487–491PubMedCrossRef
25.
Bhatt V, Vendrell N, Nau K, Crumb D, Roy V (2010) Implementation of a standardized protocol for prevention and management of oral mucositis in patients undergoing hematopoietic cell transplantation. J Oncol Pharm Pract 16:195–204PubMedCrossRef
26.
Chen J, Seabrook J, Fulford A, Rajakumar I (2017) Icing oral mucositis: oral cryotherapy in multiple myeloma patients undergoing autologous hematopoietic stem cell transplant. J Oncol Pharm Pract 23:116–120PubMedCrossRef
27.
Mori T, Aisa Y, Yamazaki R, Mihara A, Ikeda Y, Okamoto S (2006) Cryotherapy for the prevention of high-dose melphalan-induced oral mucositis. Bone Marrow Transplant 38:637–638PubMedCrossRef
28.
Ohbayashi Y, Imataki O, Ohnishi H, Iwasaki A, Ogawa T, Inagaki N, Shigeta H, Ohue Y, Tasaka T, Kitanaka A, Kubota Y, Tanaka T, Ishida T, Miyake M (2008) Multivariate analysis of factors influencing oral mucositis in allogeneic hematopoietic stem cell transplantation. Ann Hematol 87:837–845PubMedCrossRef
29.
Sato A, Saisho-Hattori T, Koizumi Y, Minegishi M, Iinuma K, Imaizumi M (2006) Prophylaxis of mucosal toxicity by oral propantheline and cryotherapy in children with malignancies undergoing myeloablative chemo-radiotherapy. Tohoku J Exp Med 210:315–320PubMedCrossRef
30.
Vokurka S, Bystricka E, Scudlova J, Mazur E, Visokaiova M, Vasilieva E, Brandejsova R, Chvojkova I, Vrabcova M, Vitkova J, Mjartanova D, Vodickova M, Bockova J, Streinerova K (2011) The risk factors for oral mucositis and the effect of cryotherapy in patients after the BEAM and HD-l-PAM 200 mg/m(2) autologous hematopoietic stem cell transplantation. Eur J Oncol Nurs 15:508–512PubMedCrossRef
31.
Vokurka S, Chvojkova I, Svoboda T, Brandejsova R, Jungova A, Bystricka E, Jindra P (2014) The impact of oral cryotherapy and oral and gastrointestinal mucositis after autologous stem cell transplantation. Eur J Oncol Nurs 18:228–229PubMedCrossRef
32.
Vokurka S, Svoboda T, Jungova A, Karas M, Koza V (2012) Oral cryotherapy can significantly reduce oral mucositis but not acute GVHD incidence in Flu/Mel conditioning allo-SCT. Bone Marrow Transplant 47:739–741PubMedCrossRef
33.
Svanberg A, Ohrn K, Birgegard G (2015) Caphosol((R)) mouthwash gives no additional protection against oral mucositis compared to cryotherapy alone in stem cell transplantation. A pilot study. Eur J Oncol Nurs 19:50–53PubMedCrossRef
34.
de Paula EF, Bezinelli LM, da Graca Lopes RM, Nascimento Sobrinho JJ, Hamerschlak N, Correa L (2015) Efficacy of cryotherapy associated with laser therapy for decreasing severity of melphalan-induced oral mucositis during hematological stem-cell transplantation: a prospective clinical study. Hematol Oncol 33:152–158CrossRef
35.
Katranci N, Ovayolu N, Ovayolu O, Sevinc A (2012) Evaluation of the effect of cryotherapy in preventing oral mucositis associated with chemotherapy-a randomized controlled trial. Eur J Oncol Nurs 16:339–344PubMedCrossRef
36.
Baydar M, Dikilitas M, Sevinc A, Aydogdu I (2005) Prevention of oral mucositis due to 5-fluorouracil treatment with oral cryotherapy. J Natl Med Assoc 97:1161–1164PubMedPubMedCentral
37.
Cascinu S, Fedeli A, Fedeli SL, Catalano G (1994) Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis. Eur J Cancer B Oral Oncol 30B:234–236PubMedCrossRef
38.
Nikoletti S, Hyde S, Shaw T, Myers H, Kristjanson LJ (2005) Comparison of plain ice and flavoured ice for preventing oral mucositis associated with the use of 5 fluorouracil. J Clin Nurs 14:750–753PubMedCrossRef
39.
Papadeas E, Naxakis S, Riga M, Kalofonos C (2007) Prevention of 5-fluorouracil-related stomatitis by oral cryotherapy: a randomized controlled study. Eur J Oncol Nurs 11:60–65PubMedCrossRef
40.
Sorensen JB, Skovsgaard T, Bork E, Damstrup L, Ingeberg S (2008) Double-blind, placebo-controlled, randomized study of chlorhexidine prophylaxis for 5-fluorouracil-based chemotherapy-induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) in gastrointestinal malignancies. Cancer 112:1600–1606PubMedCrossRef
41.
Rocke LK, Loprinzi CL, Lee JK, Kunselman SJ, Iverson RK, Finck G, Lifsey D, Glaw KC, Stevens BA, Hatfield AK et al (1993) A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil-related stomatitis. Cancer 72:2234–2238PubMedCrossRef
42.
Edelman MJ, Gandara DR, Perez EA, Lau D, Lauder I, Turrell C, Uhrich M, Meyers F (1998) Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy. Investig New Drugs 16:69–75CrossRef
43.
Gandara DR, Edelman MJ, Crowley JJ, Lau DH, Livingston RB (1997) Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study. Cancer Chemother Pharmacol 41:75–78PubMedCrossRef
44.
Dreicer R, Propert KJ, Kuzel T, Kirkwood JM, O'Dwyer PJ, Loehrer PJ (1997) A phase II trial of edatrexate in patients with advanced renal cell carcinoma. An Eastern Cooperative Oncology Group study. Am J Clin Oncol 20:251–253PubMedCrossRef
45.
Kakoei SG, A., Nakhaee, N (2013) Effect of cryotherapy on oral mucositis in patients with head and neck cancers receiving radiotherapy. Int J Radiat Res 11: 117–120
46.
Wang L, Gu Z, Zhai R, Zhao S, Luo L, Li D, Zhao X, Wei H, Pang Z, Wang L, Liu D, Wang Q, Gao C (2015) Efficacy of oral cryotherapy on oral mucositis prevention in patients with hematological malignancies undergoing hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials. PLoS One 10:e0128763PubMedPubMedCentralCrossRef
47.
Riley P, Glenny AM, Worthington HV, Littlewood A, Clarkson JE, McCabe MG (2015) Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy. Cochrane Database Syst Rev: CD011552
48.
Cho YK, Sborov DW, Lamprecht M, Li J, Wang J, Hade EM, Gao Y, Tackett K, Williams N, Benson DM, Efebera YA, Rosko AE, Devine SM, Poi M, Hofmeister CC, Phelps MA (2017) Associations of high-dose melphalan pharmacokinetics and outcomes in the setting of a randomized cryotherapy trial. Clin Pharmacol Ther 102:511–519PubMedPubMedCentralCrossRef
49.
Johansson JE, Bratel J, Hardling M, Heikki L, Mellqvist UH, Hasseus B (2019) Cryotherapy as prophylaxis against oral mucositis after high-dose melphalan and autologous stem cell transplantation for myeloma: a randomised, open-label, phase 3, non-inferiority trial. Bone Marrow Transplant 54(9):1482–1488. https://​doi.​org/​10.​1038/​s41409-019-0468-6 CrossRefPubMed
50.
Sung L, Robinson P, Treister N, Baggott T, Gibson P, Tissing W, Wiernikowski J, Brinklow J, Dupuis LL (2017) Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation. BMJ Support Palliat Care 7:7–16PubMedCrossRef
51.
Marchesi F, Tendas A, Giannarelli D, Viggiani C, Gumenyuk S, Renzi D, Franceschini L, Caffarella G, Rizzo M, Palombi F, Pisani F, Romano A, Spadea A, Papa E, Canfora M, Pignatelli A, Cantonetti M, Arcese W, Mengarelli A (2017) Cryotherapy reduces oral mucositis and febrile episodes in myeloma patients treated with high-dose melphalan and autologous stem cell transplant: a prospective, randomized study. Bone Marrow Transplant 52:154–156PubMedCrossRef
52.
Idayu Mat Nawi R, Lei Chui P, Wan Ishak WZ, Hsien Chan CM (2018) Oral cryotherapy: prevention of oral mucositis and pain among patients with colorectal cancer undergoing chemotherapy. Clin J Oncol Nurs 22:555–560PubMedCrossRef
53.
Zhang WLL, Lu YW, Zhen JC, Zhang XL (2011) Intervention research on preventing oral mucositis after using high dose methotrexate chemotherapy in osteosarcoma by gargling with calcium folinic. Chinese Phamaceutical Journal 14:1126–1128
54.
Dos Reis PE, Ciol MA, de Melo NS, Figueiredo PT, Leite AF, Manzi Nde M (2016) Chamomile infusion cryotherapy to prevent oral mucositis induced by chemotherapy: a pilot study. Support Care Cancer 24:4393–4398PubMedCrossRef
55.
Yokomizo H, Yoshimatsu K, Hashimoto M, Ishibashi K, Umehara A, Yoshida K, Fujimoto T, Watanabe K, Ogawa K (2004) Prophylactic efficacy of allopurinol ice ball for leucovorin/5-fluorouracil therapy-induced stomatitis. Anticancer Res 24:1131–1134PubMed
56.
Okada N, Hanafusa T, Abe S, Sato C, Nakamura T, Teraoka K, Abe M, Kawazoe K, Ishizawa K (2016) Evaluation of the risk factors associated with high-dose chemotherapy-induced dysgeusia in patients undergoing autologous hematopoietic stem cell transplantation: possible usefulness of cryotherapy in dysgeusia prevention. Support Care Cancer 24:3979–3985PubMedCrossRef
57.
Dumontet C, Sonnet A, Bastion Y, Salles G, Espinouse D, Coiffier B (1994) Prevention of high dose L-PAM-induced mucositis by cryotherapy. Bone Marrow Transplant 14:492–494PubMed
58.
Farrington M, Cullen L, Dawson C (2014) Cryotherapy is a simple nursing intervention for oral mucositis. ORL Head Neck Nurs 32:13–15PubMed
Metadaten
Titel
Systematic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines
Publikationsdatum
14.12.2019
Erschienen in
Supportive Care in Cancer / Ausgabe 5/2020
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-019-05217-x

Weitere Artikel der Ausgabe 5/2020

Supportive Care in Cancer 5/2020 Zur Ausgabe

Original Article

CaringGuidance™ after breast cancer diagnosis eHealth psychoeducational intervention to reduce early post-diagnosis distress

Original Article

Is the prognostic nutritional index a prognostic and predictive factor in metastatic non-small cell lung cancer patients treated with first-line chemotherapy?

Review Article

Distress screening and supportive care referrals used by telephone-based health services: a systematic review

Review Article

Inter-rater reliability in performance status assessment among healthcare professionals: an updated systematic review and meta-analysis

Original Article

Invasive mucormycosis during treatment for acute lymphoblastic leukaemia—successful management of two life-threatening diseases

Original Article

Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise